With Realignment Plan Set, Invitrogen Expects Acquisitions, IT Improvements to Drive Growth | GenomeWeb

Invitrogen officials last week pointed to heavy investments in acquisitions, improvements in the firm's information technology infrastructure, and its planned divisional and sales force realignment as key growth drivers for the company in 2006 and beyond.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.